Diaceutics' Mission of Partnerships in Companion Diagnostics Resonates With the Themes of AACR 2019 | Diaceutics

Diaceutics’ Mission of Partnerships in Companion Diagnostics Resonates With the Themes of AACR 2019

March 29th, 2019

This year’s American Association for Cancer Research (AACR) meeting is taking a team approach against fighting cancer. In alignment with the meeting’s theme of “Integrative Cancer Science, Global Impact, Individualized Patient Care,” much of the content and messaging resonating so far highlights the need for a collaborative effort, with a focus on immuno-oncology (IO). This “collaborative” effort involves all parties across the ecosystem: pharma, clinical trial researchers, laboratories, patients, families, etc. Even the human body itself is enlisted to aid in the fight against cancer through its own immune system, as well as the genetic code to help better predict what therapies will work. 

The mission of Diaceutics all along has been one of forming partnerships to foster earlier accurate diagnosis and effective treatment, in oncology in particular and general medicine overall. As a leading data analytics and implementation service provider in diagnostic commercialization, Diaceutics aids and abets collaboration between labs and pharma with the goal of driving better testing to enable better treatment decisions for patients. Whether it is providing precision medicine data analytics on next generation sequencing or leveraging anonymized patient diagnostic testing data on specific biomarker tests, such as PD-L1 or FLT3, Diaceutics specializes in delivering data-driven insights from lab data analysis to pharma to aid in the development of companion diagnostics for targeted therapies. From assisting pharma with diagnostic partner selection to target test profile development, Diaceutics is a purveyor of specialized insight into the global gamut of diagnostic testing, helping pharma tailor diagnostics to treatment pathways and, ultimately, targeting the right test to the right patient. 

Diaceutics mission aligns with much of the hot topics of research to be presented at AACR 2019, including new developments in:

Delegates from Diaceutics will be onsite at AACR 2019. Arrange to meet one of our experts on diagnostic commercialization by clicking here

Webinars & Podcasts

August 20th, 2019
Podcast: How Diaceutics is repairing the diagnostic testing ecoystem for patients worldwide
Diaceutics CEO, Peter Keeling joins Pat Kenny on Newstalk FM to discuss how analyzing Big Data to implement better diagnostic testing can help patients access better treatment options for cancer and other life-threatening diseases.
July 5th, 2019
Liquid Biopsy in NSCLC
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

October 21st, 2019
Pharma Precision Medicine Readiness Report 2019
March 16th, 2018
PM Readiness Report 2018 Summary
View all reports


June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications